ManageChatDiscover
70020

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

Internal Medicine

Abstract

Background: Hepatitis C virus (HCV) infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet (ombitasvir/ paritaprevir/ritonavir) in combination with ribavirin was effective and generally well tolerated in treatment of chronic HCV infected patients with end stage renal disease (ESRD) on hemodialysis. However, limited published data are known about the usefulness of this regimen for treatment of HCV patients with ESRD on hemodialysis.
Aim of the work: The aim of this study was to evaluate the safety and efficacy of treatment regimen of ombitasvir (OBV) 25 mg /paritaprevir (PTV) 150 mg /ritonavir (RTV) 100 mg plus generic ribavirin (RBV) 200 mg in Egyptian HCV-infected naive patients with ESRD on regular hemodialysis.
Patients and methods: A prospective cohort study involved 40 chronic HCV on regular hemodialysis patients, who were eligible for treatment with combined oral antiviral therapy.
Results: The results showed that thirty-five patients [35/40(87.5%)] completed 12 weeks of HCV therapy; they had a virological response at end of therapy and sustained virological response. Anemia was the main observed side effect which lead to discontinuation of the treatment in five patients (12.2%). As these patients were not responding to anemia correction measures (blood transfusion, erythropoietin-stimulating agents, and modification of RBV dose).
Conclusion: OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD on regular hemodialysis.

DOI

10.21608/ijma.2020.21730.1068

Keywords

Direct Acting Antiviral Drugs, End Stage Renal Disease, hepatitis C, Viral infection, Hemodialysis

Authors

First Name

Naglaa

Last Name

El-Gendy

MiddleName

Atef

Affiliation

2Department of Hepatogastroenterology and Infectious Diseases, Faculty of Medicine for Girls, Al-Azhar University, Egypt.

Email

drnaglaaelgendy@yahoo.com

City

Cairo

Orcid

-

First Name

Fathiya

Last Name

EL-Raey

MiddleName

Mostafa

Affiliation

Department of Hepatogastroenterology and Infectious Diseases, Damietta Faculty of Medicine, Al-Azhar University, Egypt.

Email

faresmd76@yahoo.com

City

Damietta

Orcid

-

First Name

Sherif

Last Name

Nassib

MiddleName

A

Affiliation

Department of Internal Medicine, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt

Email

s.nasib@gmail.com

City

-

Orcid

-

First Name

Noha

Last Name

Elsadany

MiddleName

-

Affiliation

Department of Internal Medicine, Damietta Faculty of Medicine, Al-Azhar University, Egypt

Email

n.saadany@domazhermedicine.edu.eg

City

Damietta

Orcid

-

Volume

2

Article Issue

1

Related Issue

10770

Issue Date

2020-01-01

Receive Date

2019-12-30

Publish Date

2020-01-01

Page Start

313

Page End

319

Print ISSN

2636-4174

Online ISSN

2682-3780

Article File

IJMA_Volume 2_Issue 1_Pages 313-319.pdf

PDF . 261.0kB

Link

https://ijma.journals.ekb.eg/article_70020.html

Detail API

https://ijma.journals.ekb.eg/service?article_code=70020

Order

22

Type

Original Article

Type Code

816

Publication Type

Journal

Publication Title

International Journal of Medical Arts

Publication Link

https://ijma.journals.ekb.eg/

MainTitle

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis

Details

Type

Article

Created At

22 Jan 2023